Moderate Hypofractionation Shows Good Safety Outcomes in Breast Cancer
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 16, 2024 -- For patients with breast cancer, moderate hypofractionation (MHF) shows an improved safety profile, cosmesis, and quality of life compared with conventional fractionation (CF), with equivalent oncologic outcomes, according to a study published online Sept. 11 in The BMJ.
Shing Fung Lee, M.B.B.S., from the National University Hospital in Singapore, and colleagues conducted a systematic review and meta-analysis of randomized controlled trials focusing on CF (daily fractions of 1.8 to 2 Gy reaching 50 to 50.4 Gy), MHF (2.65 to 3.3 Gy for 13 to 16 fractions), and/or ultra-hypofractionation (UHF; schedule of five fractions) for breast cancer. Fifty-nine articles representing 35 trials with 20,237 patients were assessed.
The researchers found that for MHF versus CF, the risk ratios for grade ≥2 acute radiation dermatitis were 0.54 and 0.68 following breast-conserving therapy and mastectomy, respectively. Hyperpigmentation and grade ≥2 breast shrinkage occurred less often after MHF than CF, with risk ratios of 0.77 and 0.92, respectively, in the combined breast-conserving therapy and mastectomy population. Differences in hyperpigmentation and breast shrinkage were not statistically significant in the breast-conserving therapy-only trials. For breast-conserving therapy and mastectomy populations combined, the risk ratio for grade ≥2 acute radiation dermatitis was not significantly different for UHF versus MHF. Compared with CF, MHF was associated with improved cosmesis and quality of life, while data on UHF were less conclusive. Similar survival and recurrence outcomes were seen for UHF, MHF, and CF.
"These findings justify the wider adoption of moderate hypofractionation as the preferred approach, given its balance of therapeutic efficacy and improved safety," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
Long-Course Chemoradiotherapy Preferred TNT Regimen for Rectal Cancer
THURSDAY, Sept. 12, 2024 -- For patients with locally advanced rectal cancer pursuing organ preservation, long-course chemoradiotherapy (LCCRT) is the preferred total neoadjuvant...
Breast Arterial Calcifications May Be Marker for Future Heart Disease
WEDNESDAY, Sept. 11, 2024 -- Breast arterial calcifications (BAC) identified on mammography are associated with the development of both atherosclerotic cardiovascular disease...
Palliative Low-Dose Radiotherapy Improves Pain in Hepatic Cancer
TUESDAY, Sept. 10, 2024 -- For adults with hepatocellular carcinoma or liver metastases, low-dose liver radiotherapy plus best supportive care improve pain compared with best...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.